Display options
Cite
Shibad V, Bootwala A, Mao C, et al. L2pB1 Cells Contribute to Tumor Growth Inhibition. Front Immunol. 2021;12:722451doi: 10.3389/fimmu.2021.722451.
Shibad, V., Bootwala, A., Mao, C., Bader, H., Vo, H., Landesman-Bollag, E., Guo, C., Rubio, A., Near, R., Gao, W., Challa, S., Chukka, V., Gao, J., Kelly, A., Landesman, T., VanHelene, T., & Zhong, X. (2021). L2pB1 Cells Contribute to Tumor Growth Inhibition. Frontiers in immunology, 12722451. https://doi.org/10.3389/fimmu.2021.722451
Shibad, Varuna, et al. "L2pB1 Cells Contribute to Tumor Growth Inhibition." Frontiers in immunology vol. 12 (2021): 722451. doi: https://doi.org/10.3389/fimmu.2021.722451
Shibad V, Bootwala A, Mao C, Bader H, Vo H, Landesman-Bollag E, Guo C, Rubio A, Near R, Gao W, Challa S, Chukka V, Gao J, Kelly A, Landesman T, VanHelene T, Zhong X. L2pB1 Cells Contribute to Tumor Growth Inhibition. Front Immunol. 2021 Sep 23;12:722451. doi: 10.3389/fimmu.2021.722451. eCollection 2021. PMID: 34630396; PMCID: PMC8495424.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2021 Sep 23;12:722451. doi: 10.3389/fimmu.2021.722451. eCollection 2021.

L2pB1 Cells Contribute to Tumor Growth Inhibition.

Frontiers in immunology

Varuna Shibad, Ali Bootwala, Changchuin Mao, Hanna Bader, Hung Vo, Esther Landesman-Bollag, Conrad Guo, Angel Rubio, Richard Near, Wenda Gao, Sreekar Challa, Vennela Chukka, Jeffrey Gao, Avery Kelly, Tamar Landesman, Tyler VanHelene, Xuemei Zhong

Affiliations

  1. Hematology Oncology Section, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, MA, United States.
  2. Department of Graduate Medical Studies, Boston University School of Medicine, Boston, MA, United States.
  3. Antagen Institute for Biomedical Research, Boston, MA, United States.
  4. Department of Pharmacology, Boston University School of Medicine, Boston, MA, United States.
  5. Sharon High School, Sharon, MA, United States.
  6. Lynbrook High School, San Jose, CA, United States.
  7. Brookline High School, Brookline, MA, United States.

PMID: 34630396 PMCID: PMC8495424 DOI: 10.3389/fimmu.2021.722451

Abstract

Natural IgM (nIgM) antibodies play critical roles in cancer immunosurveillance. However, the role of B-1 B cells, the lymphocytes that produce nIgM, remains to be elucidated. L2pB1 cells, a subpopulation of B-1 B cells, have a unique poly-self-reactive nIgM repertoire and are capable of phagocytosis, potent antigen presentation, and immunomodulation. Using an inducible knock-in and knockout mouse model, we investigated the effect of the loss of L2pB1 cells in a B16F10 melanoma model. Our results show active tumor infiltration of L2pB1 cells in wild type mice, and conversely, depletion of L2pB1 cells results in larger tumor mass and increased angiogenesis.

Copyright © 2021 Shibad, Bootwala, Mao, Bader, Vo, Landesman-Bollag, Guo, Rubio, Near, Gao, Challa, Chukka, Gao, Kelly, Landesman, VanHelene and Zhong.

Keywords: 3D tumor spheroids; L2pB1 cells; colon cancer; lipoptosis; melanoma; natural IgM

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. J Transl Med. 2014 Jan 30;12:30 - PubMed
  2. Biotechnol J. 2008 Oct;3(9-10):1172-84 - PubMed
  3. Oncol Rep. 2015 Sep;34(3):1106-14 - PubMed
  4. J Immunol. 2012 Sep 1;189(5):2338-47 - PubMed
  5. Hum Antibodies. 2002;11(4):131-42 - PubMed
  6. J Exp Med. 2014 May 5;211(5):943-59 - PubMed
  7. Methods Find Exp Clin Pharmacol. 2005 Apr;27(3):185-91 - PubMed
  8. Cancer Res. 2003 Nov 15;63(22):7995-8005 - PubMed
  9. Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4498-503 - PubMed
  10. Mol Cancer Ther. 2007 Jan;6(1):326-33 - PubMed
  11. Cancer Res. 1973 Oct;33(10):2349-53 - PubMed
  12. Cancer Res. 2019 Jan 1;79(1):159-170 - PubMed
  13. Cancer Res. 2004 Jun 1;64(11):3900-6 - PubMed
  14. Immun Inflamm Dis. 2014 Dec;2(4):254-61 - PubMed
  15. Immunobiology. 2014 May;219(5):357-66 - PubMed
  16. J Exp Med. 2014 Jun 2;211(6):1243-56 - PubMed
  17. Cancer Immunol Res. 2016 Dec;4(12):1027-1037 - PubMed
  18. Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12659-64 - PubMed
  19. Eur J Immunol. 2007 Sep;37(9):2405-10 - PubMed
  20. J Clin Oncol. 2013 Mar 1;31(7):860-7 - PubMed
  21. Cell Signal. 2011 Jun;23(6):1030-40 - PubMed
  22. J Immunol. 2015 Jan 1;194(1):13-20 - PubMed
  23. Mol Immunol. 2011 Jun;48(11):1292-300 - PubMed
  24. N Biotechnol. 2009 Jun;25(5):294-8 - PubMed
  25. Biophys J. 2013 Apr 2;104(7):1605-14 - PubMed
  26. J Immunol. 2017 Sep 15;199(6):2020-2029 - PubMed
  27. Cell Mol Life Sci. 2018 Jan;75(2):225-240 - PubMed
  28. Ann N Y Acad Sci. 2015 Dec;1362:77-85 - PubMed
  29. J Immunol. 2005 Aug 15;175(4):2278-85 - PubMed
  30. Prog Exp Tumor Res. 1988;32:17-68 - PubMed
  31. Immunotherapy. 2017 Mar;9(4):347-360 - PubMed
  32. Nat Immunol. 2001 Mar;2(3):261-8 - PubMed
  33. Eur J Immunol. 2012 Jan;42(1):120-9 - PubMed
  34. Arthritis Rheum. 2011 Mar;63(3):597-602 - PubMed
  35. Stem Cells. 2009 Mar;27(3):543-9 - PubMed
  36. Arthritis Rheum. 2009 Dec;60(12):3734-43 - PubMed

Publication Types

Grant support